Luc Dochez

Mr. Dochez is a Managing Partner at DROIA Genetic Diseases and a Partner at DROIA Oncology Ventures. He is a (co)-founder of various biotech companies such as Montis Biosciences, Pharvaris and Vico Therapeutics.

Dochez was Chief Executive Officer of Tusk Therapeutics from May 2015 until its acquisition by Roche in September 2018. He joined Tusk from Prosensa Holding N.V. where he served as Chief Business Officer and Senior Vice President of Business Development for a period of seven years until its acquisition by BioMarin Pharmaceutical Inc.

Earlier in his career, he served as Vice President of Business Development at TiGenix, Director Business Development at Methexis Genomics, and a consultant at Arthur D. Little. Luc holds a Pharm.D. degree and a postgraduate degree in business economics from the University of Leuven (Belgium) and an MBA from Vlerick Management School (Belgium). Luc serves on the Board of Directors of Erytech, Vico Therapeutics, Montis Biosciences, and Volastra Therapeutics.